Prescription Opioids and Risk of Dementia or Cognitive Decline: A Prospective Cohort Study
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Objectives: To determine whether prescription opioid use is associated with higher dementia risk or greater cognitive decline. Design: Prospective cohort study. Setting: Group Health, an integrated healthcare delivery system. Participants: Community‐dwelling individuals aged 65 and older without dementia with at least 10 years of Group Health enrollment at baseline (N = 3,434; median age 74). Measurements: The Cognitive Abilities Screening Instrument (CASI) was administered every 2 years. Low scores triggered detailed evaluation, and a multidisciplinary committee assigned dementia diagnoses. From computerized pharmacy data, cumulative opioid exposure was defined as total standardized doses (TSDs) dispensed over 10 years (excluding the most recent year because of possible prodromal symptoms). For comparison, use of nonsteroidal anti‐inflammatory drugs (NSAIDs), characterized similarly, was examined. Dementia risk was analyzed using Cox proportional hazards models and CASI trajectory using linear regression models and generalized estimating equations. Results: Seven hundred ninety‐seven participants (23%) developed dementia over a mean follow‐up of 7.3 years; 637 (19%) had possible or probable Alzheimer's disease. For cumulative opioid use, the hazard ratios (HRs) for dementia were 1.06 (95% confidence interval (CI) = 0.88–1.26) for 11 to 30 TSDs, 0.88 (95% CI = 0.70–1.09) for 31 to 90 TSDs, and 1.29 (95% CI = 1.02–1.62) for 91 or more TSDs, versus 0 to 10 TSDs. A similar pattern was seen for NSAID use. Heavier opioid use was not associated with more‐rapid cognitive decline. Conclusion: People with the heaviest opioid or NSAID use had slightly higher dementia risk than people with little or no use. These results may reflect an effect of chronic pain on cognition or residual confounding. Although opioids have other risks, little evidence of long‐term cognitive harm specific to opioids was found.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Screening for Depression in Well Older Adults: Evaluation of a Short Form of the CES-D
Andresen, E. M., Malmgren, J. A., Carter, W. B., & Patrick, D. L. (1994) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(18)30622-6 · Cited by 5,403 · cited 2×
“Depression was defined as a CES-D score of 10 or more.(23) Information about comorbid illnesses and medication use was retrieved from GH databases.”
MethodEstimation of Latent Ability Using a Response Pattern of Graded Scores
Samejima, F. (1969) · Psychometrika · doi:10.1007/bf03372160 · Cited by 2,194
Microglia in neurodegenerative disease
Perry, V. H., Nicoll, J. A. R., & Holmes, C. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17 · Cited by 1,543 · cited 6×
“In addition, autopsy studies have shown neuropathological findings in young drug abusers similar to those seen with Alzheimer’s disease (AD).7,8 Opioids modulate the behavior of microglia,7 immune cells in the brain that mediate inflammation, which may contribute to neurodegenerative diseases, including AD.9 Finally,…”
BackgroundInfluentialChronic back pain is associated with decreased prefrontal and thalamic gray matter density
Apkarian, A. V., Sosa, Y., Sonty, S., Levy, R. M., Harden, R. N., Parrish, T. B., & Gitelman, D. R. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2541-04.2004 · Cited by 1,434
The effect of pain on cognitive function: A review of clinical and preclinical research
Moriarty, O., McGuire, B. E., & Finn, D. P. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.01.002 · Cited by 1,122
Dementia and Alzheimer Disease Incidence: A Prospective Cohort Study
Kukull, W. A., Higdon, R., Bowen, J. D., McCormick, W. C., Teri, L., Schellenberg, G. D., van Belle, G., Jolley, L., & Larson, E. B. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1737 · Cited by 806 · cited 3×
“ACT has been described elsewhere.(12) In brief, from 1994 through 1996, 2,581 community-dwelling adults aged 65 and older without dementia were recruited from among GH members living in or near Seattle, Washington.”
BackgroundMethodInfluentialSelf-citationAnthony, I. C., Norrby, K. E., Dingwall, T., Carnie, F. W., Millar, T., Arango, J. C., Robertson, R., & Bell, J. E. (2010) · Brain · doi:10.1093/brain/awq263 · Cited by 156 · cited 1×
“In addition, autopsy studies have shown neuropathological findings in young drug abusers similar to those seen with Alzheimer’s disease (AD).(7,8) Opioids modulate the behavior of microglia,(7) immune cells in the brain that mediate inflammation, which may contribute to neurodegenerative diseases, including AD.”
Result
Cited by
Whitlock, E. L., Diaz-Ramirez, L. G., Glymour, M. M., Boscardin, W. J., Covinsky, K. E., & Smith, A. K. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.1622 · Cited by 414
Mielke, M. M., Aggarwal, N. T., Vila‐Castelar, C., Agarwal, P., Arenaza‐Urquijo, E. M., Brett, B., Brugulat‐Serrat, A., DuBose, L. E., Eikelboom, W. S., Flatt, J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12662 · Cited by 198
Ralph, S. J., & Espinet, A. J. (2018) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-170042 · Cited by 160
Tang, A. S., Oskotsky, T., Havaldar, S., Mantyh, W. G., Bicak, M., Solsberg, C. W., Woldemariam, S., Zeng, B., Hu, Z., Oskotsky, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28273-0 · Cited by 45
Metadata
- Authors
- Dublin, S., Walker, R. L., Gray, S. L., Hubbard, R. A., Anderson, M. L., Yu, O., Crane, P. K., & Larson, E. B.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2015-08
- Volume
- 63
- Issue
- 8
- Pages
- 1519-1526
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W1622836462
- Cited by
- 121
- References
- 7
- FWCI
- 7.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.